EVOTEC

EVOTEC, founded in 1993, is a global platform company specializing in drug discovery and development services. Operating within the business services sector, the firm leverages a data-driven multimodality platform to advance both proprietary and partnered research. By integrating innovative technologies, EVOTEC addresses complex pharmaceutical challenges, focusing on the discovery of first-in-class and best-in-class therapeutic products. The company maintains a robust pipeline, providing comprehensive solutions that span from biomarker discovery to chemical development and regulatory support.

With a workforce of 1,000-5,000 employees, EVOTEC maintains a significant operational footprint across 10 global locations. The organization emphasizes a collaborative model, working seamlessly with academic institutions, venture capitalists, and pharmaceutical partners to translate scientific research into clinical assets. Meet EVOTEC's team to learn about their leadership and the diverse expertise driving their high-throughput screening and precision medicine initiatives. Their operational strategy focuses on sustainable growth and the delivery of high-quality drug discovery services, ensuring that effective therapeutics are made available to patients worldwide.

Publicly traded under the ticker NASDAQ: EVO, the company demonstrates strong market presence and financial stability. With annual revenue reaching $886.1M, EVOTEC continues to secure strategic funding, including significant debt and private equity investments from entities like the European Investment Bank and Novo Holdings. Explore financial highlights for detailed metrics regarding their capital structure and long-term investment performance. By combining advanced biotechnology with a versatile business strategy, EVOTEC remains a key player in the global pharmaceutical landscape, consistently addressing critical medical needs through its integrated drug discovery and manufacturing services.